Selected research
Industry Research
Sorafenib Industry Research Report 2026
Market perspective
The global Sorafenib market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Sorafenib is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Sorafenib is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Sorafenib is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Sorafenib include Mylan, Bayer, Natco Pharma and Cipla, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Sorafenib market in terms of revenue (US$ million) and, where applicable, sales volume (units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sorafenib Market by Company
Mylan
Bayer
Natco Pharma
Cipla
Sorafenib Segment by Type
Patented Drugs
Generic Drugs
Sorafenib Segment by Application
Kidney Cancer
Thyroid Cancer
Liver Cancer
Other
Sorafenib Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sorafenib market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sorafenib and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sorafenib.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Sorafenib manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Sorafenib by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Sorafenib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Patented Drugs
- Generic Drugs
Applications
- Kidney Cancer
- Thyroid Cancer
- Liver Cancer
- Other
Companies covered
- Mylan
- Bayer
- Natco Pharma
- Cipla
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Sorafenib Market Size (2021-2032)
- 2.2.2 Global Sorafenib Sales (2021-2032)
- 2.2.3 Global Sorafenib Market Average Price (2021-2032)
- 2.3 Sorafenib by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Patented Drugs
- 2.3.3 Generic Drugs
- 2.4 Sorafenib by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Kidney Cancer
- 2.4.3 Thyroid Cancer
- 2.4.4 Liver Cancer
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Sorafenib Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sorafenib Sales (units) of Manufacturers (2021-2026)
- 3.3 Global Sorafenib Revenue of Manufacturers (2021-2026)
- 3.4 Global Sorafenib Average Price by Manufacturers (2021-2026)
- 3.5 Global Sorafenib Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sorafenib, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sorafenib, Product Type & Application
- 3.8 Global Manufacturers of Sorafenib, Established Date
- 3.9 Global Sorafenib Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mylan
- 4.1.1 Mylan Company Information
- 4.1.2 Mylan Business Overview
- 4.1.3 Mylan Sorafenib Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mylan Sorafenib Product Portfolio
- 4.1.5 Mylan Recent Developments
- 4.2 Bayer
- 4.2.1 Bayer Company Information
- 4.2.2 Bayer Business Overview
- 4.2.3 Bayer Sorafenib Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bayer Sorafenib Product Portfolio
- 4.2.5 Bayer Recent Developments
- 4.3 Natco Pharma
- 4.3.1 Natco Pharma Company Information
- 4.3.2 Natco Pharma Business Overview
- 4.3.3 Natco Pharma Sorafenib Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Natco Pharma Sorafenib Product Portfolio
- 4.3.5 Natco Pharma Recent Developments
- 4.4 Cipla
- 4.4.1 Cipla Company Information
- 4.4.2 Cipla Business Overview
- 4.4.3 Cipla Sorafenib Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Cipla Sorafenib Product Portfolio
- 4.4.5 Cipla Recent Developments
5 Global Sorafenib Market Scenario by Region
- 5.1 Global Sorafenib Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sorafenib Sales by Region: 2021-2032
- 5.2.1 Global Sorafenib Sales by Region: 2021-2026
- 5.2.2 Global Sorafenib Sales by Region: 2027-2032
- 5.3 Global Sorafenib Revenue by Region: 2021-2032
- 5.3.1 Global Sorafenib Revenue by Region: 2021-2026
- 5.3.2 Global Sorafenib Revenue by Region: 2027-2032
- 5.4 North America Sorafenib Market Facts & Figures by Country
- 5.4.1 North America Sorafenib Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Sorafenib Sales by Country (2021-2032)
- 5.4.3 North America Sorafenib Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Sorafenib Market Facts & Figures by Country
- 5.5.1 Europe Sorafenib Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Sorafenib Sales by Country (2021-2032)
- 5.5.3 Europe Sorafenib Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Sorafenib Market Facts & Figures by Country
- 5.6.1 Asia Pacific Sorafenib Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Sorafenib Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Sorafenib Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Sorafenib Market Facts & Figures by Country
- 5.7.1 South America Sorafenib Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Sorafenib Sales by Country (2021-2032)
- 5.7.3 South America Sorafenib Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Sorafenib Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Sorafenib Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Sorafenib Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Sorafenib Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Sorafenib Sales by Type (2021-2032)
- 6.1.1 Global Sorafenib Sales by Type (2021-2032) & (units)
- 6.1.2 Global Sorafenib Sales Market Share by Type (2021-2032)
- 6.2 Global Sorafenib Revenue by Type (2021-2032)
- 6.2.1 Global Sorafenib Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Sorafenib Revenue Market Share by Type (2021-2032)
- 6.3 Global Sorafenib Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Sorafenib Sales by Application (2021-2032)
- 7.1.1 Global Sorafenib Sales by Application (2021-2032) & (units)
- 7.1.2 Global Sorafenib Sales Market Share by Application (2021-2032)
- 7.2 Global Sorafenib Revenue by Application (2021-2032)
- 7.2.1 Global Sorafenib Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Sorafenib Revenue Market Share by Application (2021-2032)
- 7.3 Global Sorafenib Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Sorafenib Value Chain Analysis
- 8.1.1 Sorafenib Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Sorafenib Production Mode & Process
- 8.2 Sorafenib Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Sorafenib Distributors
- 8.2.3 Sorafenib Customers
9 Global Sorafenib Analyzing Market Dynamics
- 9.1 Sorafenib Industry Trends
- 9.2 Sorafenib Industry Drivers
- 9.3 Sorafenib Industry Opportunities and Challenges
- 9.4 Sorafenib Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst